ABSTRACT
Background: The prevalence of cancers had co-existed with COVID-19 infection globally. Some of these diseases are hypertension, diabetes, asthma, cancer co-existing with COVID-19 infection. The study therefore assessed the possible induction of ovarian cancer markers due to COVID-19 combination drugs in albino rats
Method: Healthy female albino rats were selected and acclimatized for two weeks. The rats were grouped and administered standard drug combinations in standard doses of chloroquine 10mg/kg, hydroxychloroguine 6.5mg/kg, ivermectin 200mcg/kg, zinc 2.5mg/kg. azithromycin
5mg/kg, lopinavir/ritonavir 4/1mg/kg, selenium 3.33mg/kg and diethylstilbeterol as positive control for twenty-eight days. The rats were euthanized using chloroform. Samples collected were assayed for weight and lipid indices.
Fraction of serum sample was used to assay for the ovarian cancer markers according to manufacturer's protocol.
Results: Concentration of Ovarian cancer markers had the following results (P-value <0.05): Control was (1.819), Std was (0.04988), Comb 7 was (0.03933), Comb 8 was (0.01833), Comb 9 was (0.007333).
Elevation was seen in the order CON > STD > COMB 7 > COMB 8 > COMB 9. COMB 9 caused the lowest elevation of CA 125, followed by COMB 8 and lastly COMB 7. But there is a higher elevation of CA 125 with the negative control (Manufacturer’s Standard) and the positive control (diethylstilbesterol).
Conclusion: These results showed reduction in ovarian cancer markers. Despite this, there is need to take caution in the use of drug combinations in ovarian cancer co-existing with COVID-19 infection
